Related Experiment Videos
Issues in accelerating the pace of development for neuroprotective agents
1Department of Psychiatry, Mount Sinai School of Medicine 10029-6574, USA.
Alzheimer Disease and Associated Disorders
|January 1, 1996
Summary
Developing new Alzheimer disease treatments requires early detection markers and improved clinical trial designs. Addressing regulatory hurdles is crucial for advancing neuroprotective agents and Alzheimer therapeutics.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trial Design
Background:
- Alzheimer disease (AD) therapeutics development is slow.
- Early identification of presymptomatic patients is lacking.
- Current clinical trial methodologies are not optimized for AD drug development.
Purpose of the Study:
- To review challenges in Alzheimer disease drug development.
- To propose solutions for advancing neuroprotective agents.
- To address issues in clinical trials and regulatory processes.
Main Methods:
- Literature review of current Alzheimer disease research.
- Analysis of clinical trial methodologies and regulatory frameworks.
- Synthesis of challenges and potential solutions.
Main Results:
- Need for early diagnostic markers for presymptomatic AD identification.
- Clinical trials require adaptation for prolonged durations, large sample sizes, and novel outcome measures.
- Regulatory pathways discourage development of drugs for complex, lengthy trials.
Conclusions:
- Advances in early detection and modified clinical trial designs are essential for accelerating Alzheimer disease therapeutics.
- Addressing regulatory barriers is critical for the successful development of neuroprotective agents.